BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:duvakitug readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of duvakitug\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07184996-1@assetmemo.bio
DTSTAMP:20261121T004043Z
DTSTART;VALUE=DATE:20280509
DTEND;VALUE=DATE:20280510
SUMMARY:duvakitug: Phase 3 readout est. (NCT07184996)
DESCRIPTION:duvakitug\, phase 3\, Ulcerative Colitis.\nStudy: An Induction 
 Study to Investigate the Efficacy and Safety of Duvakitug in Participants 
 With Moderately to Severely Active Ulcerative Colitis\nEstimated primary c
 ompletion: 9 May 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/duvakitug#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07184996
URL:https://assetmemo.bio/drug/duvakitug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07812116-1@assetmemo.bio
DTSTAMP:20261121T004043Z
DTSTART;VALUE=DATE:20280616
DTEND;VALUE=DATE:20280617
SUMMARY:duvakitug: Phase 2 readout est. (NCT07812116)
DESCRIPTION:duvakitug\, phase 2\, Hidradenitis Suppurativa.\nStudy: A Study
  to Investigate Efficacy and Safety of Duvakitug in Adult Participants Wit
 h Moderate to Severe Hidradenitis Suppurativa\nEstimated primary completio
 n: 16 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/duva
 kitug#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07812116
URL:https://assetmemo.bio/drug/duvakitug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07923383-1@assetmemo.bio
DTSTAMP:20261121T004043Z
DTSTART;VALUE=DATE:20280808
DTEND;VALUE=DATE:20280809
SUMMARY:duvakitug: Phase 1 readout est. (NCT07923383)
DESCRIPTION:duvakitug\, phase 1\, Ulcerative Colitis.\nStudy: An Open-label
 \, DDI Study to Investigate the Effects of Duvakitug on the PK of Selected
  Cytochrome P450 Substrates\nEstimated primary completion: 8 August 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/duvakitug#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07923383
URL:https://assetmemo.bio/drug/duvakitug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07185009-1@assetmemo.bio
DTSTAMP:20261121T004043Z
DTSTART;VALUE=DATE:20280921
DTEND;VALUE=DATE:20280922
SUMMARY:duvakitug: Phase 3 readout est. (NCT07185009)
DESCRIPTION:duvakitug\, phase 3\, Ulcerative Colitis.\nStudy: A Maintenance
  Study to Investigate the Efficacy and Safety of Duvakitug in Participants
  With Moderately to Severely Active Ulcerative Colitis\nEstimated primary 
 completion: 21 September 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/duvakitug#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07185009
URL:https://assetmemo.bio/drug/duvakitug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07184931-1@assetmemo.bio
DTSTAMP:20261121T004043Z
DTSTART;VALUE=DATE:20290514
DTEND;VALUE=DATE:20290515
SUMMARY:duvakitug: Phase 3 readout est. (NCT07184931)
DESCRIPTION:duvakitug\, phase 3\, Crohn's Disease.\nStudy: An Induction Stu
 dy to Investigate the Efficacy and Safety of Duvakitug in Participants Wit
 h Moderately to Severely Active Crohn's Disease\nEstimated primary complet
 ion: 14 May 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/duv
 akitug#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07184931
URL:https://assetmemo.bio/drug/duvakitug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07184944-1@assetmemo.bio
DTSTAMP:20261121T004043Z
DTSTART;VALUE=DATE:20290813
DTEND;VALUE=DATE:20290814
SUMMARY:duvakitug: Phase 3 readout est. (NCT07184944)
DESCRIPTION:duvakitug\, phase 3\, Crohn's Disease.\nStudy: A Maintenance St
 udy to Investigate the Efficacy and Safety of Duvakitug in Participants Wi
 th Moderately to Severely Active Crohn's Disease\nEstimated primary comple
 tion: 13 August 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /duvakitug#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07184944
URL:https://assetmemo.bio/drug/duvakitug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
